WELL Health Technologies Partners with AliveCor to Deliver AI-Enhanced Cardiac Monitoring with Cardiologist Oversight Across Canada
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (“WELL” or the “Company”), a leading digital healthcare provider dedicated to improving patient outcomes through technology, today announced a strategic collaboration with AliveCor, Inc. (“AliveCor”), the global leader in AI-powered personal electrocardiogram (ECG) devices. This partnership integrates WELL Health’s expanding national network of Canadian-licensed cardiologists with AliveCor’s Kardia platform, allowing Canadian users to receive timely clinician review of their heart health data, directly from home.
Through this partnership, Canadians using AliveCor’s Kardia ECG technology will now have the option to request a Clinician Review from a WELL Health-registered cardiologist. Once a user records an ECG with their Kardia device, the ECG data can be submitted through the Kardia mobile application. Within 24 hours, a cardiologist from WELL Health’s network evaluates the recording, providing a detailed clinical interpretation. This review serves as a “second set of eyes” on the patient’s heart metrics, confirming or refining the initial analysis generated by AliveCor’s AI algorithms. Each clinician review includes written guidance and potential next steps, helping users better understand their cardiac health and make informed decisions about care.
AliveCor’s Kardia platform is grounded in advanced, clinically validated artificial intelligence cleared to detect serious cardiac conditions. The Health Canada-approved AI algorithms embedded within the Kardia app can instantly identify the three most common arrhythmias in a short, 30-second ECG recording. With more than 350 million ECGs recorded globally, Kardia is recognized as one of the most thoroughly validated personal ECG solutions available. By pairing this AI technology with WELL Health’s clinician review service, patients benefit from a hybrid approach: automated, immediate AI detection followed by expert human evaluation. The physician review ensures that any potential issues flagged by the AI are assessed in the context of each patient’s clinical profile, providing an extra layer of safety and reassurance.
From a business perspective, WELL Health benefits from the service through revenue generated for each cardiologist review performed. This creates a scalable clinical services revenue stream while simultaneously expanding the reach of WELL’s specialist physician network into the fast-growing remote cardiac monitoring market. The collaboration reflects a broader trend toward digital healthcare solutions that blend advanced AI technology with human expertise, enhancing patient care while optimizing operational efficiency.
The service is particularly relevant in the current Canadian healthcare landscape, where access to cardiology services is constrained. Elective cardiology wait times in Canada have increased by 53% over the last year, with patients waiting an average of 15.3 weeks for specialist consultations. By enabling patients to receive expert cardiac evaluation remotely, the WELL-AliveCor partnership helps accelerate clinical decision-making, reduce unnecessary emergency room visits, and improve patient confidence in managing their heart health from home.
Dina Sergi, CEO of WELL Health Diagnostic Centres, commented on the partnership, stating, “This collaboration pairs the clinical expertise of WELL’s cardiologist network with some of the most advanced AI-powered cardiac monitoring technology in the world. By providing clinician review to AliveCor’s AI-driven analysis, we are helping patients get answers faster, easing pressure on the healthcare system, and creating a new, scalable revenue stream for WELL. This is a significant step forward in bringing high-quality, accessible cardiac care to Canadians.”
Navneet Malpani, Senior Vice President of Partner Alliances at AliveCor, also highlighted the benefits of the partnership: “AliveCor is committed to delivering the most clinically validated heart care tools to patients worldwide. By partnering with WELL Health, Canada’s leader in modern outpatient care, we are providing Canadian customers with an essential layer of clinical oversight. Patients can now receive expert guidance from certified cardiologists without the need to wait for in-person appointments, giving them peace of mind and timely insights into their cardiac health.”
The integration of WELL Health’s cardiologist network with AliveCor’s Kardia platform exemplifies the evolving model of remote, AI-supported healthcare, where patients can access professional care without leaving their homes. The Kardia Clinician Review service ensures that users benefit from rapid, reliable cardiac evaluations, combining automated detection with human clinical expertise. This hybrid approach mitigates risks associated with solely AI-based monitoring, provides context-specific medical interpretation, and empowers patients to take proactive steps in managing their cardiovascular health.
Looking ahead, WELL Health plans to explore additional ways to support the adoption of AliveCor’s suite of Kardia products across its national network. This initiative represents the first phase of a multi-stage collaboration, with potential future developments including the deployment of AliveCor’s Kardia 12L, a pocket-sized, AI-powered 12-lead ECG system designed for use in primary care, urgent care, and outpatient settings. Introducing the Kardia 12L within WELL’s clinic network could further expand point-of-care cardiac diagnostics, offering rapid, on-site heart health assessments in addition to remote monitoring capabilities.
The partnership also aligns with the broader trend of digital-first healthcare, which has accelerated in recent years. Patients increasingly seek convenient, accessible, and reliable health monitoring solutions, while healthcare providers are leveraging technology to optimize care delivery, reduce delays, and improve patient outcomes. By combining advanced AI technology with clinician oversight, WELL Health and AliveCor are creating a model that addresses these evolving patient and system needs.
Cardiologists participating in the Clinician Review program play a critical role in validating AI-detected anomalies, ensuring accurate interpretations, and recommending appropriate interventions. The structured feedback provided through the review service not only guides patients but also strengthens the overall reliability of AI-assisted cardiac monitoring, providing confidence to both users and clinicians. This collaborative model demonstrates how digital health solutions can enhance the effectiveness of existing healthcare infrastructure rather than replace human expertise.
Furthermore, the partnership between WELL Health and AliveCor contributes to the long-term expansion of remote cardiac monitoring in Canada, a market projected to grow rapidly as AI-powered devices and telehealth solutions gain broader adoption. By offering a solution that integrates AI with direct clinician engagement, the service addresses key barriers in remote patient monitoring, including interpretation accuracy, timely access to specialist insight, and actionable guidance for patient care.
In conclusion, the WELL Health and AliveCor collaboration represents a strategic fusion of cutting-edge AI technology and clinical expertise, enabling Canadians to monitor and manage their heart health more effectively than ever before. The partnership is designed to deliver tangible benefits for patients, healthcare providers, and the broader health system by reducing wait times, increasing accessibility to specialist care, and generating new revenue streams for clinical services. As digital healthcare continues to transform the landscape of patient care, initiatives like this highlight the potential of AI-assisted, physician-validated remote monitoring to enhance outcomes, empower patients, and drive innovation in healthcare delivery.
Source link: https://www.businesswire.com
